MS
GSK icon

Murray Stahl’s GSK GSK Stock Holding History

Murray Stahl’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Sell
24,046
-373
-2% -$19.7K 0.01% 149
2026
Q1 		$1.35M Sell
24,419
-473
-2% -$25.6K 0.01% 144
2025
Q4 		$1.22M Sell
24,892
-473
-2% -$22.1K 0.02% 151
2025
Q3 		$1.09M Sell
25,365
-12,027
-32% -$470K 0.01% 162
2025
Q2 		$1.44M Sell
37,392
-1,273
-3% -$48.6K 0.02% 150
2025
Q1 		$1.5M Sell
38,665
-1,200
-3% -$43.9K 0.02% 139
2024
Q4 		$1.35M Buy
39,865
+1,673
+4% +$60.2K 0.02% 151
2024
Q3 		$1.56M Buy
38,192
+13,027
+52% +$533K 0.02% 139
2024
Q2 		$969K Hold
25,165
– – 0.02% 165
2024
Q1 		$1.08M Hold
25,165
– – 0.02% 155
2023
Q4 		$933K Buy
25,165
+227
+0.9% +$8.15K 0.02% 160
2023
Q3 		$904K Buy
24,938
+1,100
+5% +$39K 0.02% 166
2023
Q2 		$850K Buy
23,838
+1,000
+4% +$35.9K 0.02% 173
2023
Q1 		$813K Buy
22,838
+9,560
+72% +$334K 0.02% 175
2022
Q4 		$467K Hold
13,278
– – 0.01% 219
2022
Q3 		$391K Buy
13,278
+361
+3% +$13.7K 0.01% 234
2022
Q2 		$703K Hold
12,917
– – 0.01% 187
2022
Q1 		$703K Sell
12,917
-43
-0.3% -$2.34K 0.01% 207
2021
Q4 		$714K Sell
12,960
-400
-3% -$20.8K 0.02% 211
2021
Q3 		$638K Hold
13,360
– – 0.01% 220
2021
Q2 		$665K Sell
13,360
-5,440
-29% -$261K 0.01% 215
2021
Q1 		$839K Buy
18,800
+80
+0.4% +$3.63K 0.02% 196
2020
Q4 		$861K Buy
18,720
+160
+0.9% +$7.35K 0.03% 190
2020
Q3 		$873K Hold
18,560
– – 0.04% 183
2020
Q2 		$946K Buy
18,560
+243
+1% +$12.5K 0.03% 171
2020
Q1 		$868K Sell
18,317
-560
-3% -$29.9K 0.04% 156
2019
Q4 		$1.11M Hold
18,877
– – 0.03% 158
2019
Q3 		$1.01M Sell
18,877
-800
-4% -$41.2K 0.03% 166
2019
Q2 		$984K Buy
19,677
+139
+0.7% +$6.97K 0.03% 176
2019
Q1 		$1.02M Buy
+19,538
New +$976K 0.03% 170

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Murray Stahl's GSK Position: Q2 2026 in Review

Murray Stahl reduced its GSK (GSK) stake by 1.5% in Q2 2026, selling an estimated $19.7K and leaving 24,046 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #149.

Murray Stahl first reported a position in GSK in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.56M in Q3 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Murray Stahl held 24,046 shares of GSK worth $1.26M as of Q2 2026.
  • Murray Stahl sold 373 GSK shares in Q2 2026, an estimated $19.7K.
  • GSK made up 0.01% of Murray Stahl's portfolio in Q2 2026, its #149 holding.
  • Murray Stahl first reported a position in GSK in Q1 2019 and has held it in 30 quarters since.
  • Murray Stahl's GSK position peaked at $1.56M in Q3 2024.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.